The New England journal of medicine
-
Randomized Controlled Trial Comparative Study
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers. ⋯ The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (ClinicalTrials.gov number, NCT00021060.)